TABLE 3.
One‐year rates and HRs for bleeding events in patients with atrial fibrillation and history of gastrointestinal cancer by subgroups according to initial prescription claim for a DOAC or VKA
| Outcome | Group | Bleeding events, n | Unweighted rate per 100 person‐years (95% CI) | Weighted rate per 100 person‐years (95% CI) | Weighted HR (95% CI) |
|---|---|---|---|---|---|
| Active cancer | |||||
| Any bleeding | DOAC | 55 | 11.92 (9.15, 15.52) | 11.70 (8.97, 15.51) | 1.12 (0.71, 1.76) |
| VKA | 25 | 9.03 (6.10, 13.36) | 10.24 (6.90, 15.82) | Ref | |
| GI bleeding | DOAC | 27 | 5.66 (3.88, 8.26) | 5.52 (3.81, 8.30) | 1.00 (0.53, 1.88) |
| VKA | 14 | 5.00 (2.96, 8.45) | 5.42 (3.17, 10.03) | Ref | |
| Upper gastrointestinal cancer | |||||
| Any bleeding | DOAC | 11 | 8.62 (4.77, 15.56) | 8.79 (4.88, 17.41) | 0.66 (0.27, 1.61) |
| VKA | <5 | 6.74 (2.53, 17.95) | 13.61 (2.38, 196.93) | Ref | |
| GI bleeding | DOAC | 10 | 7.83 (4.21, 14.56) | 8.17 (4.40, 16.85) | 0.61 (0.25, 1.52) |
| VKA | <5 | 6.74 (2.53, 17.95) | 13.61 (.38, 196.93) | Ref | |
| Colorectal cancer | |||||
| Any bleeding | DOAC | 115 | 10.65 (8.87, 12.78) | 10.88 (9.06, 13.17) | 0.94 (0.68, 1.29) |
| VKA | 52 | 10.78 (8.21, 14.14) | 11.52 (8.74, 15.45) | Ref | |
| GI bleeding | DOAC | 55 | 4.95 (3.80, 6.45) | 5.08 (3.92, 6.71) | 0.92 (0.58, 1.46) |
| VKA | 27 | 5.47 (3.75, 7.97) | 5.49 (3.76, 8.31) | Ref | |
Counts were suppressed for observations with less than five incidents, to prevent disclosure of potentially identifiable information.
Abbreviations: DOAC, direct oral anticoagulant; VKA, vitamin K antagonist.